Research ArticlePERTUSSIS

A cocktail of humanized anti–pertussis toxin antibodies limits disease in murine and baboon models of whooping cough

+ See all authors and affiliations

Science Translational Medicine  02 Dec 2015:
Vol. 7, Issue 316, pp. 316ra195
DOI: 10.1126/scitranslmed.aad0966

Outsmarting whooping cough to help infants

Whooping cough continues to cause severe illness and death in infants worldwide. Whereas antibiotics are effective in the rare cases when pertussis is diagnosed early, medical interventions are limited and invasive during later stages of the disease. In an effort to help critically ill or at-risk infants, Nguyen et al. developed a cocktail of two humanized antibodies that show promise for halting disease progression. The antibodies both bind to the key virulence factor pertussis toxin at distinct sites, mitigating its damaging effects. In murine and baboon models, antibody treatment increased bacterial clearance and curtailed the rise in white blood cell counts associated with poor prognosis in infants.


Despite widespread vaccination, pertussis rates are rising in industrialized countries and remain high worldwide. With no specific therapeutics to treat disease, pertussis continues to cause considerable infant morbidity and mortality. The pertussis toxin is a major contributor to disease, responsible for local and systemic effects including leukocytosis and immunosuppression. We humanized two murine monoclonal antibodies that neutralize pertussis toxin and expressed them as human immunoglobulin G1 molecules with no loss of affinity or in vitro neutralization activity. When administered prophylactically to mice as a binary cocktail, antibody treatment completely mitigated the Bordetella pertussis–induced rise in white blood cell counts and decreased bacterial colonization. When administered therapeutically to baboons, antibody-treated, but not untreated control animals, experienced a blunted rise in white blood cell counts and accelerated bacterial clearance rates. These preliminary findings support further investigation into the use of these antibodies to treat human neonatal pertussis in conjunction with antibiotics and supportive care.


Despite widespread vaccination, pertussis remains a considerable public health concern. In recent decades, infection rates have markedly risen in industrialized countries, reaching a 60-year high in the United States in 2012. This rise appears to be due to a variety of factors including increased surveillance, strain drift, waning immunity after acellular vaccination, and a vaccine-induced T helper 1 cell (TH1)/TH2 response instead of the more effective TH1 response induced by whole-cell vaccines and infection (1). Worldwide, pertussis remains a major cause of infant death, claiming ~195,000 lives annually (2). Pertussis is of greatest concern for unimmunized infants because they experience the most severe symptoms, including pneumonia and pulmonary hypertension due to severe leukocytosis (3). In the absence of alternatives, aggressive interventions including leukodepletion and exchange transfusion have been proposed to remove white blood cells (WBCs) (4).

It is generally accepted that, in the long-term, an improved vaccine formulation better able to prevent disease transmission will be required (1, 5, 6). In the meantime, there remains a need for pertussis-specific therapeutics to treat infants with severe disease because antibiotics are only effective in the early stages, typically before diagnosis. Even after bacteria can no longer be cultured, symptoms persist for many weeks, presumably due to residual toxins.

Whereas Bordetella pertussis produces a wide array of toxins and adhesins, several lines of evidence point to the pertussis toxin (PTx) as a critical virulence factor. This AB5 toxin is essential for full bacterial pathogenicity (7), exhibiting local and systemic effects through its enzymatically active A subunit and its receptor-binding B subunit. The overall effects of PTx are inhibition of the innate immune response and induction of leukocytosis. Specifically, in mouse models of pertussis infection, the presence of PTx decreases proinflammatory chemokine and cytokine production (8), reduces neutrophil recruitment to the lungs, and increases bacterial burden (9). Whereas these effects have not all been demonstrated in human disease, PTx does appear important in primates as well. In vitro, PTx has been shown to have an inhibitory effect on human dendritic cell migration that is predicted to slow their recruitment to secondary lymph nodes and subsequent activation of T cells (10). In human infants, PTx production positively correlates with the extreme lymphocytosis that can lead to pulmonary hypertension (11). Finally, whereas most acellular vaccines are composed of PTx in combination with other antigens, the Danish vaccine relies on a monocomponent PTx and reports no increase in symptomatic infection (12).

Accordingly, a high-serum anti-PTx antibody concentration is considered to correlate with protection (6, 13), and passive immunization with anti-PTx serum has been recognized as a potential therapeutic modality for neonatal pertussis. In the past two decades, two human polyclonal anti-PTx immunoglobulin preparations were tested and showed promise for treating pertussis in newborns (1416). However, treatment with polyclonal antisera can be problematic because of low and variable neutralizing capacities as well as an unreliable supply. For passive immunization, monoclonal antibodies provide a considerable advantage because they can be selected for high affinity and potent neutralizing abilities. For these reasons, the high-titer intravenous immunoglobulin product to treat respiratory syncytial virus was replaced with a single neutralizing antibody in 1996.

To treat pertussis, we combined two anti-PTx monoclonal antibodies selected to achieve high potency and to limit the possibility of allelic variants that could escape neutralization. Among the numerous anti-PTx monoclonal antibodies that have been evaluated over the past three decades, the murine 1B7 (m1B7) and 11E6 (m11E6) antibodies stand out as uniquely protective in mouse models of pertussis infection (17, 18). However, murine antibodies are no longer considered suitable for use in humans because of their immunogenicity. Here, we cloned and humanized the m1B7 and m11E6 antibodies, produced them as human immunoglobulin G1 (IgG1) antibodies in Chinese hamster ovary (CHO) cells, and characterized them in vitro. The humanized antibodies were assessed in a murine challenge model using a recent human B. pertussis isolate and compared to the high-titer pertussis intravenous immunoglobulin (P-IVIG) preparation used in recent human clinical trials (15). Finally, the antibodies were tested in a newly described baboon model considered highly relevant for the development of pertussis therapeutics (19). Collectively, the data support further animal modeling to assess the potential for passive immunotherapies to mitigate human neonatal pertussis.


m1B7 and m11E6 antibody genes were cloned and humanized

As the first step in humanization, the m1B7 and m11E6 antibody heavy and light chain variable region genes were cloned with reverse transcription polymerase chain reaction (RT-PCR) from hybridoma cells using a degenerate primer set, and PTx-reactive genes were identified. Next, three to five humanized variants of each variable region were generated in silico, and the murine and humanized genes were cloned into eukaryotic expression vectors encoding human IgG1 heavy or κ light chain constant domains. All pairwise heavy-light chain combinations were expressed by transiently transfected CHO cells and the supernatant used to monitor specific PTx binding activity (fig. S1). Combinations yielding the highest specific activity were further analyzed after medium-scale expression and protein A purification. From these data, a single lead candidate was selected for each antibody, which exhibited similar enzyme-linked immunosorbent assay (ELISA) dose-response curves to the murine parent antibody as well as high expression (~5 to 10 pg per cell per day). Sequences of these variants are notably more human than the murine antibody sequences, as monitored by z score (table S1) (20).

Human 1B7 and 11E6 antibodies are biochemically and biophysically similar to their murine counterparts

After transient CHO cell expression, the murine, chimeric, and humanized antibodies were purified (~95%) and migrated at the expected sizes in SDS–polyacrylamide gel electrophoresis (PAGE) gels (Fig. 1A). Increased thermal stability was observed, indicating that both the human constant and humanized variable regions were stabilized relative to the murine versions (Table 1 and fig. S2).

Fig. 1. Humanized, chimeric, and murine antibodies have similar binding affinities to PTx.

(A) SDS-PAGE comparing purified murine, chimeric (ch), and humanized (hu) variants of 1B7 and 11E6 in reduced and nonreduced forms as indicated. Molecular weight standards (kD) are shown in lane 1. (B) Indirect ELISA comparing the binding of all three versions of each antibody to PTx: murine (triangle), chimeric (circle), humanized (square), and isotype control (×) antibodies are shown. The absorbance data were normalized such that the maximum signal is 1.0; each sample was run in duplicate, and each assay was performed at least three times with different protein preparations.

Table 1. Biochemical characterization of 1B7 and 11E6 antibodies.

nd, not determined.

View this table:

Binding to PTx was initially assessed by ELISA (Fig. 1B) and competition ELISA (fig. S3). The murine and chimeric versions of each antibody, presenting identical variable region amino acid sequences but appended with murine and human constant domains, respectively, exhibited very similar binding affinities as measured by competition ELISA (Table 1). We next collected kinetic binding data using surface plasmon resonance (SPR) with immobilized antibody. The SPR-measured association and dissociation rates were similar for the murine, chimeric, and humanized variants, yielding affinities within error for all three 1B7 variants [Kd (dissociation constant), ~0.7 ± 0.5 nM] and all three 11E6 variants (Kd, ~2.3 ± 0.7 nM; Table 1 and fig. S4).

The binary combination of hu1B7 and hu11E6 antibodies is synergistic

Not only do hu1B7 and hu11E6 bind PTx tightly, but as monoclonal antibodies, they exhibit ~100-fold and 10-fold higher PTx-specific binding titers, respectively, compared to the P-IVIG used previously to treat human infants (15) (Fig. 2A). Furthermore, PTx can simultaneously bind to hu1B7 and m11E6, suggesting that their effects may be synergistic (Fig. 2B). Indeed, whereas either antibody protects CHO cells against PTx-mediated morphological changes at ~70:1 (hu1B7) and ~40:1 (hu11E6) molar ratios, an equimolar binary combination exhibits enhanced protection (~20:1; Fig. 3A), which is more neutralizing than an equivalent P-IVIG dose (~120:1; Fig. 3B) (17). Accordingly, a 1:1 molar ratio of hu1B7 and hu11E6 was selected for subsequent animal protection studies.

Fig. 2. hu1B7 and hu11E6 antibodies have higher anti-PTx titers than high-titer P-IVIG.

(A) hu1B7 and hu11E6 antibodies and high-titer P-IVIG were assessed for binding to PTx by ELISA. An ELISA plate was coated with PTx, blocked, and incubated with the indicated concentrations of P-IVIG, hu1B7, or hu11E6. (B) Sandwich ELISA was used to assess simultaneous binding of hu1B7 and hu11E6 antibodies according to the scheme indicated with goat anti-mouse–Fc–horseradish peroxidase conjugate (Gαm-Fc-HRP) used for detection. Each sample was run in duplicate, and each assay was repeated at least three times.

Fig. 3. The binary combination of hu1B7 and hu11E6 antibodies is synergistic and more potent than P-IVIG in vitro.

The CHO cell clustering assay was used to determine the molar ratio of antibodies to PTx required for complete neutralization of CHO morphology changes. (A) Different ratios of hu1B7 and hu11E6 were compared to determine the most potent ratio. (B) An equimolar ratio of hu1B7 and hu11E6 was compared to the same ratio of murine antibodies and P-IVIG. Results depict average of three replicate experiments; statistical significance (*P < 0.05) was determined by single-factor analysis of variance (ANOVA) and Tukey’s test with α = 0.05. Ab, antibody.

hu1B7 and hu11E6 antibodies protect mice prophylactically from B. pertussis infection

Mice are not a natural host for B. pertussis; however, they share some characteristics of human disease and were used to develop all vaccines to date. In particular, the rate of bacterial clearance in immunized mice after aerosol challenge correlates with vaccine efficacy in children (21). Previously, Sato et al. (17, 18) performed murine protection studies with m1B7 and m11E6 antibodies using intracerebral and inhalation models with B. pertussis strain 18-323. Because this study was preparatory for nonhuman primate studies, we replaced strain 18-323, which infects mice efficiently but is a hypervirulent strain of atypical B. pertussis lineage, with strain D420, a recent human clinical isolate used to develop the baboon model and which expresses the dominant alleles of major virulence factors (22). Pilot studies determined that prophylaxis with 5 μg of m1B7 antibody followed by infection with 5× 106 colony-forming units (CFU) of D420 resulted in statistically significant differences in WBC counts, bacterial colonization, and weight gain over a 10-day period with groups of six animals (fig. S5).

Recognizing that antibodies with human constant domains will be cleared from the blood more rapidly than murine antibodies, we assessed the murine in vivo clearance rates of the humanized antibodies for comparison to previously measured m1B7 rates. Mice were administered chimeric or humanized antibodies or a binary cocktail of humanized antibodies (2 mg/kg, subcutaneously), and sera were collected over 14 days with anti-PTx concentrations measured by ELISA. The β elimination half-lives of ~100 hours for humanized and chimeric antibodies with human constant domains were similar and, as expected, shorter than that for m1B7 (~210 hours) (23). We used these data to estimate that a 20-μg dose of humanized antibodies would result in similar serum concentrations on day 10 as the 5-μg m1B7 dose used in pilot studies.

Accordingly, weanling mice were administered 20 μg each of a single humanized or chimeric antibody, P-IVIG, the binary humanized antibody mixture or a phosphate-buffered saline (PBS) control (n = 6 per group) before inoculation with 5× 106 CFU of B. pertussis strain D420. At 10 days after inoculation, untreated mice exhibited about fivefold increase in WBC count relative to naïve mice (Fig. 4A and table S3), lost weight (Fig. 4B), and were heavily colonized by B. pertussis (Fig. 4C). In contrast, all mice receiving monoclonal antibodies exhibited significantly decreased WBC counts as compared to PBS-treated mice (P < 0.001; Fig. 4A). Animals receiving the 1B7 antibody resembled uninfected mice more closely than those receiving only 11E6 or P-IVIG for all outcomes. This was most pronounced in terms of weight gain: mice receiving ch1B7, hu1B7, or the antibody mixture gained significantly more weight than the PBS-treated animals (P < 0.05; Fig. 4B). Mice treated with the antibody cocktail were indistinguishable from naïve animals in terms of WBC counts and weight gain and had significantly lower WBC counts than P-IVIG–treated mice (P < 0.05; Fig. 4A). Finally, mice treated with the binary antibody cocktail had ~10-fold reduced bacterial colonization compared to untreated mice (P < 0.01; Fig. 4C), similar to the reduced colonization observed for PTx-deletion strains of B. pertussis (24). P-IVIG was previously tested in human clinical trials (15, 16) with promising initial outcomes; if the correlation between performance in the mouse model holds for human outcomes, this humanized antibody combination could be more protective than P-IVIG.

Fig. 4. Prophylactic treatment with humanized antibodies protects mice against pertussis.

Mice (n = 6) were each administered 20 μg of antibody intraperitoneally 2 hours before infection with 5 × 106 CFU B. pertussis D420 bacteria. (A to C) The infection severity was assessed on day 10 by (A) CD45+ leukocyte counts (WBC), (B) weight gain, and (C) bacterial colonization of the lungs. No bacteria were recovered from uninfected animals. Means ± SE are shown; significance (*P < 0.05, **P < 0.01, and ***P < 0.001) versus PBS treatment is indicated, using Tukey’s simultaneous test. Additionally, only P-IVIG–treated mice had WBC counts distinguishable from uninfected naïve mice (P < 0.01); mice treated with hu1B7, ch1B7, or the antibody cocktail had lower WBC counts than those treated with P-IVIG at equivalent doses (P < 0.05). Only mice treated with P-IVIG and ch11E6 exhibited reduced weight gain relative to uninfected mice (P < 0.05).

hu1B7 and hu11E6 antibodies protect baboons therapeutically from infection by B. pertussis

Finally, we used a recently developed nonhuman primate model to assess the feasibility of our antibody cocktail to treat established disease. In this model, bacteria are administered intranasally and intratracheally to weanling baboons, who then exhibit symptoms of classical pertussis including colonization of the trachea, increased WBC counts, and a characteristic cough. No other clinical changes have been associated with disease (19). B. pertussis strain D420 was administered to eight weanling animals on day 0. Three days later, when the WBC count had begun to rise (>14,000/μl; table S2), the humanized antibody cocktail (20 mg/kg of each antibody) was administered intravenously to four of the animals. All eight animals were then monitored for WBC count, cough, and bacterial colonization (table S4).

Disease in the untreated animals (n = 4) was typical of the model (19): the WBC count rose into the 40,000/μl range by day 5 before beginning to decline, approaching baseline after 23 days (Fig. 5A). These animals were heavily colonized by B. pertussis (107 to 108 CFU recovered by nasopharyngeal wash on days 3 to 17) and remained elevated for the duration of the study (Fig. 5B). One control animal (C1) became moribund after exhibiting an extremely high WBC count. In contrast to the controls, all four animals receiving antibody treatment exhibited a blunted rise in WBC counts and accelerated removal of bacteria from the nasopharynx (Fig. 5C). At the time of treatment, two of the treated animals had achieved high levels of nasopharyngeal colonization (107 to 5 × 108 CFU; denoted as H1 and H2), whereas the other two treated animals experienced moderate levels of nasal carriage (~104 CFU; denoted as M1 and M2). These animals exhibited a sharp decrease in WBC counts coincident with antibody treatment. The measured antibody β-phase elimination half-life in the treated baboons was 10 ± 4 days; thus, hu1B7 and hu11E6 concentrations remained high for the duration of the study (fig. S6). ELISA detection of PTx-reactive antibodies in nasopharyngeal washes indicated that the administered antibodies were present in the mucosa of treated but not of control animals (fig. S7).

Fig. 5. Therapeutic treatment with antibody cocktail reduces leukocytosis and accelerates bacterial clearance in baboons.

Weanling baboons were inoculated with 109 to 1010 CFU B. pertussis D420 bacteria on day 0. On day 3 after infection (indicated by arrow), animals in the treatment group (n = 4) were administered hu1B7 and hu11E6 antibodies intravenously, whereas control animals (n = 4) were given nothing. (A to C) All animals were subsequently monitored for (A) WBC count, (B) bacteria recovered by nasopharyngeal wash, and (C) coughing on the days indicated. Groups shown include controls (solid black icons, dashed line, C1 to C4), treated animals that were mildly colonized (gray icons, dotted black line, M1 and M2), and treated animals that were heavily colonized (hollow icons, solid gray line, H1 and H2). (D) Serum anti-Fha titers for individual animals were used to assess endogenous immune responses. Titers were normalized to the maximum response observed for serum from a historical control baboon, collected 3 weeks after experimental infection. Serum was not available for animal C3.

Here, the baboon model exhibited variability in cough severity and clinical progression, as is seen in human pertussis (25). All the animals coughed, but this did not strongly correlate with WBC counts or the degree of bacterial colonization. Three of the four controls exhibited substantial coughing (>10 per hour) through day 9, whereas the two heavily colonized, treated animals experienced heavy bouts of coughing (60+ per hour on day 3), which diminished rapidly after antibody treatment (Fig. 5C and table S2). All treated animals exhibited reduced cough rates by day 5, with coughs reduced to <5 per hour by day 9. No other clinical observations (body temperature, weight, and activity; table S4) were found to correlate with disease. Potential variables such as insulin, histamine sensitization, and blood chemistry have not been evaluated in this model. Notably, the related bacterial strain Bordetella parapertussis, which is responsible for a small percentage of human pertussis cases, does not express PTx yet causes a similar cough in humans (25). Thus, we would not expect PTx neutralization to affect the cough except indirectly by protecting the innate immune system and the resulting enhanced bacterial clearance.

Histological examination of moribund control animal C1 revealed a normal trachea with dense bronchopneumonia and large abscesses, similar to that seen in postmortem analyses of infants that died of pertussis (3). B. pertussis was recovered from the trachea and right lung of this animal, whereas histopathology from recovering control and treated animals showed evidence of abscesses and small consolidations. Thus, the damage that occurred to the lung tissue during the first 72 hours of infection may not have had time to repair, consistent with the long-term sequelae after severe pertussis. Histopathological analyses of treated, mildly colonized animals revealed some abnormalities (fibroses and consolidations), but these animals were overall much healthier (fig. S8).

We were interested in why two treated animals were less efficiently colonized. To explore this, we evaluated baseline serum antibodies recognizing another major Bordetella antigen, filamentous hemagglutinin (Fha), by ELISA (Fig. 5D). Animals with clear pertussis symptoms had no baseline serum Fha titer but exhibited detectable levels by day 20, consistent with a primary immune response (19). The two co-housed animals with low levels of nasal carriage also had relatively high initial anti-Fha titers, which exhibited rapid increases starting on day 6, as expected for a secondary immune response (19). From one of these animals, Bordetella bronchiseptica was recovered in the nasal wash (<100 CFU) in addition to B. pertussis. Therefore, we hypothesized that baboons are subject to B. bronchiseptica infection and that concurrent exposure partially protected these two animals, as does previous B. pertussis infection (5).


Before widespread vaccination, a number of blood products and polyclonal immunoglobulins were used to treat human pertussis, some with positive, albeit poorly controlled, results (26). More recent preparations were developed on the presumption that PTx is responsible for the severe symptoms of disease, and therefore, preparations enriched in anti-PTx antibodies would mitigate the symptoms. However, this clinical strategy is limited by the expectation that only a fraction of PTx-specific antibodies in a polyclonal preparation would be neutralizing. In contrast, the monoclonal antibodies used in this study were selected specifically for their capacity to neutralize PTx, individually and synergistically. The initial feasibility data using murine and baboon models reported here support the concept of passive immunotherapy to neutralize PTx’s pathological effects.

Previously, two polyclonal anti-PTx preparations elicited by immunization with inactivated PTx were assessed in controlled trials. One showed a significant ~3-fold decrease in the number and duration of whoops versus placebo-treated children, an effect that was most pronounced when treatment was initiated within the first 7 days (14). A subsequent P-IVIG preparation used for phase 1 or 2 trials in infants showed declines in lymphocytosis and paroxysmal coughing by the third day after treatment (15). Unfortunately, phase 3 trials did not support this initial promise because the product expired before study enrollment was completed (16). Given the dosage and blood volume of infants enrolled in these studies, both achieved the goal of high and sustained anti-PTx titers but observed variable effects on clinical outcomes.

The m1B7 and m11E6 antibodies are each highly protective alone, and the combination was previously shown to function synergistically in aerosol and intracerebral murine models (18). Notably, they were more efficacious than a polyclonal anti-PTx preparation and provided significant protection when administered up to 7 days after infection as measured by survival, leukocytosis, and bacterial colonization (17). Because 11E6 is thought to competitively inhibit PTx binding to cellular receptors (18), this antibody appears to prevent the initial PTx-cell interaction but may require a 2:1 stoichiometry for complete neutralization of the two binding sites on each PTx molecule. Unlike 11E6, 1B7 appears to alter PTx intracellular trafficking such that the toxin never reaches its G protein–coupled target (27). hu1B7 and m11E6 can simultaneously bind PTx (Fig. 2), indicating that the epitopes do not overlap and supporting the hypothesis that hu1B7 and hu11E6 are synergistic by virtue of complementary mechanisms. This notion is further supported by the in vitro CHO cell neutralization data shown here, in which the humanized antibodies displayed synergy when combined in an equimolar ratio (Fig. 3). On the basis of these data, we think that synergy is highly likely, although the murine studies presented here were designed to demonstrate protection conferred by humanized antibodies against a clinically relevant strain as opposed to synergy.

The promising clinical results with P-IVIG and the availability of murine antibodies conferring in vivo protection with complementary mechanisms led us to hypothesize that humanized versions of these antibodies would efficiently block PTx activities and treat pertussis symptoms in humans. The hu1B7 and hu11E6 antibodies are biochemically similar to the original murine versions, leading to the expectation that they will exhibit similar efficacy. This was initially evaluated in a prophylactic murine aerosol model using a recent human clinical isolate. Not only did the humanized antibodies protect the chimeric antibodies, but the individual antibodies and the binary combination significantly mitigated disease in terms of weight gain, lung colonization, and WBC counts (Fig. 4).

The murine aerosol mouse model was used to develop current acellular vaccines and support their progression to human clinical trials. However, in 2012, a nonhuman primate model, which may have better predictive value for human disease, was first reported. Using this model, we observed leukocytosis and bacterial colonization in control animals, which resolved after 3 weeks, typical of the model (19). Antibody-treated animals exhibited a blunted rise in WBC counts and accelerated bacterial clearance (Fig. 5), supporting a role for these antibodies to treat pertussis in critically ill infants.

Notably, the baboon model introduces a large number of bacteria (109 to 1010 CFU) into the respiratory tract, resulting in rapid onset of disease, with WBC elevation apparent in 2 to 3 days and heavy coughing in 3 to 4 days. In contrast, humans are likely infected with a smaller inoculum through contact or aerosols, exhibiting comparable clinical symptoms 2 to 3 weeks after infection (28). This is similar to baboons experimentally infected by contact or aerosol transmission, who show peak WBC counts several weeks after infection (29). Together, these data suggest that the baboon clinical symptoms observed on day 3 correspond to human symptoms several weeks after infection. Because there are no previous data evaluating pertussis therapeutics in baboons, treatment on day 3 after infection was selected due to the rapid onset of disease in baboons, the expected antibody serum half-life, and the appearance of endogenous baboon antibody responses as early as 12 days after infection. Additional animal modeling and human clinical trials would determine the windows during which antibody treatment could affect disease outcomes.

The two baboons that were only mildly colonized with B. pertussis were likely partially protected through concurrent exposure to B. bronchiseptica. This organism is endemic in many animal populations but has not been described in baboons (25). Here, two co-housed animals were mildly colonized by B. pertussis (103 to 104 CFU recovered), with similar day 3 WBC counts and coughing as in all other animals, symptoms that resolved rapidly upon antibody administration (table S2). Protection against B. pertussis infection has been observed for mice previously infected with B. bronchiseptica (30); concurrent exposure in baboons may also provide some cross-protection. An important implication is that baboons must be protected from and monitored for B. bronchiseptica exposure before use in B. pertussis studies.

By immediately arresting PTx activities, the hu1B7/hu11E6 antibody cocktail appears to have two effects on disease progression, as observed in both the murine and baboon models. First, because PTx is directly responsible for the elevated WBC counts, blocking this activity prevents further leukocytosis, protecting against pulmonary hypertension and organ failure, the specific causes of infant death from pertussis. Second, by modifying Gi/o proteins, PTx interferes with innate immune responses, particularly chemotaxis to the lungs and subsequent oxidative burst activity by neutrophils (8, 9). Antibody-mediated blockade of these activities is expected to allow neutrophils and macrophages to more efficiently phagocytose B. pertussis, thereby resolving the pertussis infection and preventing secondary infections. Because there is no evidence to support direct antibacterial effects mediated by these antibodies, protection of the innate immune system would explain the ~10-fold reduction in bacterial colonization observed in mice (Fig. 4) and baboons (Fig. 5) after antibody treatment. These results are consistent with studies showing similar reductions in murine colonization by PTx-deficient B. pertussis and B. parapertussis strains (7, 24, 31) and the inability of acellular vaccination to prevent subsequent bacterial colonization of mice or baboons (5, 32). While the bacteria colonize the lungs, the various murine responses to PTx, including hyperinsulinemia and histamine sensitization, suggest that the toxin is widely distributed and thus antibodies are likely required systemically to neutralize PTx activities.

Two potential challenges for an antibody therapeutic to treat pertussis are maternal vaccination and early identification of exposed or high-risk infants. Currently, maternal vaccination is the leading strategy in development to protect newborns from pertussis before initiation of standard vaccination schedules at 2 months of age. The goal is to induce high levels of maternal anti-pertussis antibodies for transfer to the fetus in utero that then confer protection after birth. Although maternal vaccination is attractive for many reasons, recent uptake data in the United States indicate that with optimal health care access, 40% of newborns remain unprotected (33), whereas 86% of pregnancies covered by Medicare did not receive the vaccine (34). Moreover, the resulting infant anti-pertussis titers can be modest at birth and decay rapidly (35). This will leave many infants unprotected, and the need for a therapeutic in urgent situations will remain. The neutralizing antibodies described here could provide a complementary therapeutic strategy when maternal immunization fails. Similarly, therapeutic use of anti-pertussis antibodies will require accurate and timely identification of high-risk cases such that the therapy can be administered when it is most effective. We expect minimal interference with subsequent vaccination because only two of the many epitopes included in the vaccine would be masked by hu1B7 and hu11E6.

We believe that these data in aggregate support continued development of the hu1B7 and hu11E6 antibodies toward clinical application. To this end, we are currently planning experiments in neonatal baboons because these appear to better mimic severe pertussis observed in human neonates (36). These antibodies have affinities typical of those generated by in vivo somatic hypermutation and similar to approved antibody therapeutics, but enhanced efficacy may be attained through additional protein engineering efforts to increase the binding affinity (37) or the circulating half-life (38). The evidence presented here and in previous literature suggests that neutralizing PTx will improve recovery when added to the current standard of care; however, this notion would need to be clearly demonstrated in controlled human trials with quantitative end points before broad antibody use. In addition, given improvements in antibody manufacturing and support from nongovernmental organizations, the antibodies may be able to prevent disease in the developing world where infants are most likely to die from pertussis. Finally, these results support the notion that PTx is a major protective antigen and should continue to be a focus of future pertussis vaccines.


Study design

The objective of this study was to assess the protection conferred by two humanized anti-PTx antibodies in animal models of pertussis. In both the mouse and baboon model, strain D420, a recent clinical isolate of B. pertussis, was used to infect the animals.

An established murine model used to develop the current vaccine was used to evaluate the prophylactic protection conferred by these antibodies (17). BALB/c and C57BL/6 mice were used for the pharmacokinetic analysis and pertussis challenge, respectively. On the basis of pilot studies, groups of six mice were expected to provide statistical power to observe antibody-mediated changes in WBC counts with 80% confidence in a one-tailed test with P = 0.05 (fig. S5). Mouse studies were terminated at day 10, on the basis of pilot studies showing large differences in outcome at this time.

A weanling baboon model was recently developed that may be more representative of human disease progression as evidenced by colonization of the trachea, an increase in WBC counts, and paroxysmal coughing (19). This model was used to assess protection conferred by these antibodies when administered therapeutically on day 3 after infection, with four control animals and four treated animals. One control baboon became moribund, and data were not available after day 10 for that animal. Baboons were randomly assigned to groups, and animal caretakers and laboratory technicians were blinded. The baboon study was terminated after ~21 days or when WBC counts and degree of bacterial colonization began to approach preinfection levels.

Antibody variable region cloning and humanization

The m1B7 and m11E6 variable region genes (17) were amplified from hybridoma cells by RT-PCR using degenerate primers and cloned into pAK100 as described (39). Positive clones were identified by monoclonal phage ELISA using a PTx-coated plate (1 μg/ml in PBS; List Labs), followed by sequencing. Humanized variants were designed in silico through five different methods: (i) “veneering” (ven); (ii) “grafting of abbreviated complementarity-determining regions (CDRs)” (abb); (iii) “specificity-determining residue transfer” (sdr); and (iv) grafting of intact CDRs onto the hu4D5 framework or (v) a composite framework (fra) (27, 40). The resulting designed variable region genes were synthesized with human IgG1/κ constant domains by DNA 2.0 in pJ602 or pJ607 vectors. For chimeric constructs, murine variable regions were similarly cloned with human constant regions (39).

Protein expression and purification

For small-scale expression, plasmid DNA was transiently transfected into CHO-K1 cells (American Type Culture Collection) and purified using protein A affinity chromatography as described (39). Large-scale preparations were prepared by Catalent from polyclonal CHO cell lines, followed by protein A and anion chromatographic steps and buffer exchange into PBS. P-IVIG was obtained from the Massachusetts Public Health Biologic Laboratory (lot IVPIG-2). P-IVIG was prepared as a 4% IgG solution from the pooled plasma from donors immunized with tetranitromethane-inactivated pertussis toxoid vaccine (16).

ELISA and binding assays

For indirect PTx ELISAs, a high-binding 96-well ELISA plate (Costar) was coated with PTx (1 μg/ml). The plate was blocked with milk for 1 hour, followed by incubation with duplicate anti-PTx antibody dilutions from 50 μg/ml for 1 hour at 25°C. After washing and detection with 50 μl of goat anti-mouse–Fc–HRP (murine antibodies, Thermo Fisher), goat anti-human–Fc–HRP (chimeric and human antibodies, Thermo Fisher), or goat anti-monkey IgG (H/L)–HRP (baboon serum, Bio-Rad) (1 μg/ml), signal was developed with tetramethylbenzidine (TMB) substrate (Thermo Fisher Scientific) and quenched with 1M HCl, and the absorbance at 450 nM was recorded. To monitor antibody concentrations in cell culture supernatant, an Fc capture ELISA was used, using the protocol above with the following modifications: goat anti-human–Fc (Thermo Scientific) coat (5 μg/ml) and goat anti-human–κ–HRP (SouthernBiotech) (2 μg/ml) secondary antibody. For Fha ELISA with baboon sera, Fha coat (1 μg/ml; List Labs) and 1:10,000 dilution of goat anti-monkey–IgG (H/L)–HRP (Bio-Rad) secondary antibody was used. Data were scaled to the maximum response observed for positive control serum collected from an animal 3 weeks after infection.

PTx binding affinity was determined by both competition ELISA and SPR. For competition ELISA, an ELISA plate was coated with PTx and blocked as described above. While the plate was being blocked, 3.25 nM of each antibody in PBS–Tween milk was incubated with different concentrations of PTx (200 to 0.1 nM). The ELISA plate was washed, and 50 μl of the antibody-PTx mixtures was added. The plate was incubated for 15 min at 25°C. The plate was then washed, secondary antibody was added, and ELISA was developed as above. The resulting curves were fit to equilibrium binding equations (41) corrected for bivalent binding.

SPR analysis was performed using a Biacore 3000 (GE Healthcare; 1B7 variants) or Reichert SR7500DC (AMETEK; 11E6 variants) instrument with dextran chips. Antibodies were immobilized using standard EDC/ NHS chemistry to a level of 500 to 1000 response units as described (27). PTx was injected in duplicate at 30 or 100 μl/min (m1B7 and ch1B7), with concentrations between 5 and 200 nM diluted in running buffer [PBS or Hanks’ balanced salt solution (pH 7.4) and 0.05% Tween]. The surface was regenerated with a combination of 4 M magnesium chloride and 10 mM glycine, optimized independently for each antibody. Baseline correction was performed by subtracting simultaneous runs over an in-line control flow cell. The on- and off-rates were calculated using BIAevaluation software (Pharmacia Biosensor) or TraceDrawer (Reichert). Reported values are the average and SD of all on- and off-rates calculated for each protein.

In vitro neutralization

Inhibition of CHO cell clustering was used to determine in vitro neutralization of antibody preparations as described (27). Briefly, the antibody was serially diluted across a 96-well tissue plate from 50 nM to 1.5 pM in the presence of 5 pM PTx. Antibody and PTx were incubated for 30 min at 37°C, after which 2 × 104 freshly trypsinized CHO cells were added per well. After incubation at 37°C for 20 hours, the degree of clustering was scored as 0 (no clustering), 1 (equivocal), 2 (positive clustering), or 3 (maximal clustering). Experiments were performed in triplicate and scored independently by two researchers. Neutralizing dose is expressed as the molar ratio of antibody/PTx resulting in a score of 2.

Bacterial strain and growth

B. pertussis strain D420 was isolated from a critically ill infant in Texas in 2002 (22). Bacteria were maintained on Regan-Lowe agar (Becton Dickinson) supplemented with 10% sheep’s blood (Hemostat) with cephalexin (20 μg/ml). Liquid cultures were grown overnight in Stainer-Schölte broth with heptakis at 37°C to mid-log phase.

Ethics statement

All animal procedures were performed in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International in accordance with protocols approved by University of Texas at Austin (#2012-00084 and #13080701), Pennsylvania State University (#40029), and the University of Oklahoma Health Sciences Center (#14-072-I) Animal Care and Use Committee and the principles outlined in the Guide for the Care and Use of Laboratory Animals.

Murine pharmacokinetic assay

An in vivo pharmacokinetic study was completed using groups of six ~12-week-old female BALB/c mice as described previously (23). ch11E6, hu11E6, hu1B7, or a 1:1 mixture of hu1B7 and hu11E6 antibodies at the same total antibody concentration was diluted to 250 μg/ml in PBS, and 200 μl was injected subcutaneously. Blood samples were collected via the tail vein at seven time points between 0 and 336 hours. Antibody concentration in sera was measured by PTx ELISA. After the final time point, mice were euthanized through CO2 inhalation and cervical dislocation. To estimate the β half-life, the data were fit to a single exponential decay model: C(t) = bexp(−βt).

In vivo mouse challenge

Groups of six randomly assigned weanling C57BL/6 mice were each injected intraperitoneally with a single antibody (20 μg), P-IVIG (20 μg), or the antibody combination (10 μg of hu1B7 + 10 μg of hu11E6), or PBS 2 hours before sedation with 5% isofluorane in oxygen and inoculation with 5× 106 CFU B. pertussis strain D420 in PBS by pipetting 50 μl on the external nares. Investigators were not blinded. The percent weight change was calculated by the following formula: [(day 10 weight – day 0 weight)/day 0 weight] × 100% for each individual mouse. On day 10, mice were euthanized by CO2 inhalation, and the respiratory tract was excised for enumeration by serial plating on Regan-Lowe agar supplemented with 10% sheep’s blood (Hemostat Resources) containing cephalexin (40 μg/ml). Colonies were counted after 5 days at 37°C.

To assess the number of CD45+ WBCs, blood was collected by orbital bleed (day 10) in a microtainer containing EDTA (Becton Dickinson), and 50 μl of blood was lysed in 4 ml of red blood cell lysis solution (Alfa Aesar) for 6 min. Cells were incubated with anti-CD45-allophycocyanin conjugate, washed, and resuspended in 2% paraformaldehyde before acquisition on the LSRFortessa flow cytometer (Becton Dickinson). List mode data were then analyzed on FlowJo 7.6.1 (Tree Star), with data reported as total WBC per 40 μl of blood.

Baboon challenge study

Baboon studies were performed at the Oklahoma Baboon Research Resource at the University of Oklahoma Health Sciences Center as described previously (19). Weanling baboons were selected to be 6 to 9 months old at the time of challenge. Groups consisted of four animals based on published vaccination studies (19). The inoculum for each direct challenge was between 109 and 1010 CFU as determined by optical density and confirmed by serial dilution and plating. The bacterial inoculum (1 ml) was delivered on day 0 via intranasal and intratracheal infusion. On day 3 after infection, animals were sedated and humanized anti-PTx antibodies were administered intravenously (20 mg/kg each). After the challenge, baboons were anesthetized and evaluated twice weekly for enumeration of circulating WBC, serum antibody levels, and nasopharyngeal bacterial load. Nasopharyngeal washes were diluted and plated on Regan-Lowe plates to quantify bacterial cell counts. Video recordings of each cage allowed quantification of cough rates. Sera were assessed for antibody titers to Bordetella antigens Fha and PTx by ELISA. At the end of the study, baboons were euthanized with an intravenous injection of euthanasia solution and necropsy was performed. Tissues were embedded and stained with hematoxylin and eosin and evaluated by a veterinary pathologist.

Statistical analysis

Mean ± SE values were determined for all appropriate data. For the murine challenge experiment, one-way ANOVA with Tukey’s simultaneous test with significance (P < 0.05) was used to determine statistical significance between groups. Error bars reported in mouse, baboon, and CHO cell assay experiments represent the SE. All other errors reported are SDs.


Fig. S1. Specific activity of humanized antibody variants.

Fig. S2. Antibody thermal stability.

Fig. S3. Competition ELISA to assess solution binding affinities of purified antibodies.

Fig. S4. Binding kinetics of antibody-PTx interactions.

Fig. S5. Pilot murine protection data with recent human clinical isolate D420 and m1B7.

Fig. S6. Concentrations of anti-PTx antibodies in baboons.

Fig. S7. Detection of the hu1B7-hu11E6 combination in the nasopharyngeal wash of baboons.

Fig. S8. Histopathological analysis of lung tissue.

Table S1. Humanized antibodies are more similar to the human repertoire than the original murine antibodies.

Table S2. Baboon model challenge details.

Table S3. Tabulated mouse challenge data.

Table S4. Tabulated baboon challenge data.


  1. Acknowledgments: We thank J. Keith (NIH) for the 1B7 and 11E6 hybridomas; D. Ambrosino (Mass Biologics) for P-IVIG; T. Merkel (U.S. Food and Drug Administration) for helpful discussions; H. Sato and Y. Sato for their publications on the m1B7 and m11E6 antibodies. Funding: We acknowledge the following funding sources: NIH grant #AI066239, Norman Hackerman Advanced Research Project #003658-0019-2011, Welch F-1767, and Synthetic Biologics (J.A.M.); NIH grant #P40OD010431 and #P40OD010988 (R.F.W.). Author contributions: A.W.N., E.K.W., and J.A.M. planned, performed, and analyzed antibody humanization, antibody characterization, and baboon antibody detection experiments. J.R.L. planned, performed, and analyzed mouse pharmacokinetic experiments. E.A.P., A.W.N., E.K.W., and A.B. designed the humanized antibody sequences. J.A.M., E.T.H., L.L.G., and W.E.S. planned, performed, and analyzed mouse challenge experiments. J.A.M., M.K., J.F.P., and R.F.W. designed, planned, performed, and analyzed baboon challenge experiments. M.K. and J.A.M. supervised and designed experiments. J.A.M. wrote the first manuscript draft, and all authors contributed to manuscript revision. Competing interests: M.K. and A.B. are employed by Synthetic Biologics, which has a financial interest in hu1B7 and hu11E6 antibodies. J.A.M. has been awarded a patent no. US 20120244144 A1, “Pertussis antibodies and uses thereof.” J.A.M., A.W.N., E.K.W., and E.A.P. have jointly filed a provisional patent with Synthetic Biologics, “Humanized pertussis antibodies and uses thereof,” with the U.S. Patent and Trademark Office. This work is supported in part by funding from Synthetic Biologics. Data and materials availability: hu1B7 and hu11E6 antibodies are available upon request.
View Abstract

Related Content

Navigate This Article